Abstract Number: 2071 • ACR Convergence 2025
Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of autoimmune diseases marked by inflammation of muscle tissue and extramuscular manifestations. Their atypical…Abstract Number: 1201 • ACR Convergence 2025
Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
Background/Purpose: Lung involvement is the most frequent and severe extramuscular complication of Idiopathic Inflammatory Myopathy (IIM). The utility of pulmonary function test (PFT) monitoring for…Abstract Number: 0281 • ACR Convergence 2025
Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoinflammatory diseases that affect muscle tissue, often leading to muscle atrophy, weakness and myalgia.…Abstract Number: 2068 • ACR Convergence 2025
Comparing characteristics, diagnostics, and treatment in people with different idiopathic inflammatory myopathies using a large representative cohort
Background/Purpose: Studies of idiopathic inflammatory myopathies (IIM) are often based on the analysis of single cohorts at academic centers. We aimed to identify potential gaps…Abstract Number: 1199 • ACR Convergence 2025
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a major cause of interstitial lung disease (ILD), with high prevalence in inflammatory idiopathic myopathy (IIM), systemic sclerosis…Abstract Number: 2067 • ACR Convergence 2025
Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors
Background/Purpose: Comorbidities contribute to the disease burden in idiopathic inflammatory myopathies (IIMs). Understanding their distribution and predictors across IIM subtypes can guide tailored strategies. This…Abstract Number: 1196 • ACR Convergence 2025
Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) can be associated with significant pain and functional impairment. While the use of opioids has been documented in other inflammatory…Abstract Number: 2066 • ACR Convergence 2025
Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Traditional clinical measures are well established in idiopathic inflammatory myopathies (IIM), yet exploration of subjective well-being (SWB) remains limited. SWB assessment facilitates holistic patient…Abstract Number: 1193 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of idiopathic inflammatory myositis (IIM) and systemic sclerosis (SSc), ranging from subclinical ILD to rapidly progressive…Abstract Number: 0319 • ACR Convergence 2024
Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…Abstract Number: 1160 • ACR Convergence 2024
Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness
Background/Purpose: The quality of life, as measured by the Short Form-36 (SF-36), is reduced in patients with idiopathic inflammatory myopathies (IIM). Although endorsed by the…Abstract Number: 2076 • ACR Convergence 2024
Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience
Background/Purpose: There is a relative scarcity of studies on the effective management of Anti-signal recognition particle (anti-SRP) myositis. Recent consensus on anti-SRP myositis shows that…Abstract Number: 0327 • ACR Convergence 2024
Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…Abstract Number: 1161 • ACR Convergence 2024
Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…Abstract Number: 2078 • ACR Convergence 2024
Increased RAGE Expression in Myositis
Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »
